Description
Abacavir sulfate was first launched as Ziagen in the US for the
treatment of human immunodeficiency virus (HIV) infection, in combination with
other antiretroviral drugs. Abacavir is a carbocyclic nucleoside reverse
transcriptase inhibitor (nRTI); it is one of the most potent anti-HIV agents to
date. The compound can be prepared by an enantioselective synthesis involving
palladium-catalyzed coupling of a chloropurine with a carbocyclic allylic
diacetate. In vitro, Abacavir is a potent and selective inhibitor of HIV-1 and HIV-2
replication. Resistance to Abacavir develops more slowly than for other anti-HIV
agents. Abacavir is highly synergistic with protease inhibitors such as
Amprenavir. In clinical trials for HIV infections in adults, it produced durable
suppression in viral load. Combinations with different protease inhibitors such as
Nelfinavir, Saquinavir or Indinavir markedly reduced plasma viral load to
undetectable levels for at least 48 weeks, and significantly raised CD4+ cell
counts in adults with HIV infection, especially nRTI-naive patients. Abacavir has
a good oral availability and its penetration into CSF is much more significant
than for other anti-HIV drugs. The two major metabolites identified in humans
were the 5'-carboxylate and the 5'-glucuronide, mainly excreted via the renal
route.
Chemical Properties
White Solid
Originator
Glaxo Wellcome (UK)
Uses
A nucleoside reverse transcriptase inhibitor (NRTI)
Definition
ChEBI: An azaheterocycle sulfate salt that is the sulfate salt of the HIV-1 reverse transcriptase inhibitor abacavir.
Manufacturing Process
Treatment of 2,5-diamino-4,6-dihydroxypyrimidine (I) with
(chloromethylene)dimethylammonium chloride yielded the dichloropyrimidine
with both amino groups derivatized as amidines. Partial hydrolysis with
aqueous HCl in hot ethanol gave N-(2-amino-4,6-dichloro-pyrimidin-5-yl)-N,Ndimethylformamidene
(II). Subseqent buffered hydrolysis at pH 3.2 yielded
the (2-amino-4,6-dichloro-pyrimididin-5-ylamino)acetaldehyde (III).
Condensation chloropyrimidine (III) with (1S,4R)-4-amino-2-cyclopentene-1-
methanol (IV) in the presence of triethylamine and NaOH gave [2-amino-4-
chloro-6-(4-hydroxymethyl-cyclopent-2-enylamino)pyrimidin-5-ylamino]-
acetaldehyde (V). The correct enantiomer (IV) of racemic aminocyclopentene
was obtained by resolution of diastereomeric salts with D-dibenzoyltartaric
acid. Cyclization of (V) to the corresponding purine was accomplished with
refluxing triethyl orthoformate or diethoxymethyl acetate to give nucleoside
analogue [4-(2-amino-6-chloro-purin-9-yl)-cyclopent-2-enyl]methanol (VI).
Displacement of chloride in the purine nucleus with cyclopropyl amine in
refluxing butanol afforded abacavir. The structure of obtained compound was
confirmed by 1H NMR method and elemental analysis.
In practice it is usually used as sulfate salt.
Brand name
Ziagen (GlaxoSmithKline).
Therapeutic Function
Antiviral
General Description
Abacavir sulfate belongs to the class of human immunodeficiency virus (HIV) medicines called nucleoside reverse transcriptase inhibitors, with antiretroviral activity against HIV.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Biochem/physiol Actions
Abacavir incorporated in the cells is converted to triphosphate containing guanine analog carbovir (CBV) and it favors the generation of higher double stranded breaks (DSBs).
Synthesis
Abacavir Sulfate can be prepared by an enantioselective synthesis involving palladium-catalyzed coupling of a chloropurine with a carbocyclic allylic diacetate.
Synthesis Step: Treatment of 2,5-diamino-4,6-dihydroxypyrimidine (I) with (chloromethylene)dimethylammonium chloride yielded the dichloropyrimidine with both amino groups derivatized as amidines. Partial hydrolysis with aqueous HCl in hot ethanol gave N-(2-amino-4,6-dichloro-pyrimidin-5-yl)-N,Ndimethylformamidene (II). Subseqent buffered hydrolysis at pH 3.2 yielded the (2-amino-4,6-dichloro-pyrimididin-5-ylamino)acetaldehyde (III). Condensation chloropyrimidine (III) with (1S,4R)-4-amino-2-cyclopentene-1- methanol (IV) in the presence of triethylamine and NaOH gave [2-amino-4- chloro-6-(4-hydroxymethyl-cyclopent-2-enylamino)pyrimidin-5-ylamino]- acetaldehyde (V). The correct enantiomer (IV) of racemic aminocyclopentene was obtained by resolution of diastereomeric salts with D-dibenzoyltartaric acid. Cyclization of (V) to the corresponding purine was accomplished with refluxing triethyl orthoformate or diethoxymethyl acetate to give nucleoside analogue [4-(2-amino-6-chloro-purin-9-yl)-cyclopent-2-enyl]methanol (VI). Displacement of chloride in the purine nucleus with cyclopropyl amine in refluxing butanol afforded abacavir. The structure of obtained compound was confirmed by 1H NMR method and elemental analysis.
In practice it is usually used as sulfate salt.
